Chemopreventive effect of celecoxib in gastric cancer |
| |
Authors: | S Futagami K Suzuki T Hiratsuka T Shindo T Hamamoto N Ueki M Kusunoki K Miyake K Gudis T Tsukui C Sakamoto |
| |
Institution: | (1) Third Department of Internal Medicine, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo 113-8602, Japan |
| |
Abstract: | COX (cyclooxygenase) is one of the key enzymes involved in the synthesis of a variety of prostaglandins (PGs), some of which
have been strongly linked to inflammation. One of its two well-known isoforms, COX-2, is an inducible enzyme whose induction
and expression is dynamically regulated by growth factors, mitogens, and tumor promoters.
Several animal and clinical studies have reported the chemopreventive effect of celecoxib, a selective COX-2 inhibitor; and
in particular, a few studies have shown that celecoxib prevents the development of gastric cancer. Administration of celecoxib
also showed increases in cardiovascular risk and disruption of renal physiology. Therefore, studies hoping to clarify how
selective COX-2 inhibitors modulate gastric cancer must keep in mind that coxibs have also been linked to serious cardiovascular
events and disruption of renal physiology.
Received 12 July 2006; accepted 21 August 2006 |
| |
Keywords: | COX-2 inhibitor Celecoxib H pylori Gastric cancer Intestinal metaplasia |
本文献已被 PubMed SpringerLink 等数据库收录! |
|